|
|
GINMU >
03 紀要 >
031 Journal of Nara Medical Association >
Vol.60 No.1-2 >
Please use this identifier to cite or link to this item:
http://hdl.handle.net/10564/926
|
| Title: | IMMUNOCHEMOTHERAPY WITH INTERFERON-α, INTERLEUKIN-2, 5-FLUOROURACIL, AND CIMETIDINE FOR PATIENTS WITH ADVANCED RENAL CELL CARCINOMA |
| Authors: | Miyake, Makito
Fujimoto, Kiyohide
Tanaka, Masahiro
Hirao, Yoshihiko
Uemura, Hirotsugu
Otani, Takeshi
Yoshii, Masahito |
| Keywords: | interferon-α
interleukin-2
5-fluorouracil
cimetidine
renal cell carcinoma |
| Issue Date: | 30-Apr-2009 |
| Publisher: | 奈良医学会 |
| Citation: | Journal of Nara Medical Association Vol.60 No.1-2 p.37-47 |
| Abstract: | Introduction. We prospectively evaluated the efficacy and safety of
immunochemotherapy using INF-α, IL-2, 5-fluorouracil (5-FU), and cimetidine in patients
with metastatic renal cell carcinoma (RCC). Patients and Methods. Twenty-two patients
with metastatic RCC were given 4 weeks of initial therapy consisting of IFN-α (3-6x10^6
IU/day 3 times/week), IL-2 (0.7-1.4x10^6 JRU/day for 5 consecutive days/week), 5-FU (150
mg/m2/day for 5 consecutive days/week), and cimetidine (800 mg/day), followed by
maintenance therapy with IFN-α, IL-2, and cimetidine. The response rate, overall and
progression-free survivals, and adverse events were analyzed. Results. The median
periods of therapy and follow-up were 4.4 months (range: 0.4 33) and 28.8 months (range:
1-65), respectively. The early anti-tumor effect was a complete response in one (4.5%), a
partial response in 3 (13.6%), no change in 9 (40.9%), and progressive disease in 9
(40.9%). The 2-year progression-free and overall survival rates were 31% and 76%,
respectively. The overall survival of cytokine-naive group was higher than that of
cytokine-resistant group (p＜0.032). Adverse events of grade ≦3 occurred in 5 patients,
and 9 discontinued this therapy due to adverse events. Conclusion. The present regimen
had a low response rate despite the high incidence of adverse events and should be
limited to patients with cytokine-naive metastatic RCC. |
| URI: | http://hdl.handle.net/10564/926 |
| ISSN: | 13450069 |
| Appears in Collections: | Vol.60 No.1-2
|
Files in This Item:
| File |
Description |
Size | Format |
|---|
| 37-47p.IMMUNOCHEMOTHERAPY WITH INTERFERON-α, INTERLEUKIN-2, 5-FLUOROURACIL.pdf | | 1028Kb | Adobe PDF | View/Open |
|
All items in DSpace are protected by copyright, with all rights reserved.
|
